GSK Is Parting With Its ‘Rare Disease Gene Therapy’ Unit Instead
Walmsley progressively moves on her promise of reshaping GSK’s portfolio in a strategic overhaul of the company whereby focusing on oncology.
GSK
Patrick Vallance, GSK’s head of research, set to become UK’s scientific advisor
The move comes in the wake of GSK’s new Chief Executive Emma Walmsley undertaking a major overhaul of the company’s pharmaceuticals division with a focus on boosting productivity at the company.
